Veracyte's Global CSO/CMO Giulia Kennedy to depart Dec. 31, 2022

VERACYTE, INC.

Dr. Kennedy will leave Veracyte effective Dec. 31, 2022; separation agreement signed.
Severance includes six months' salary and up to 24 months of COBRA coverage.
She will receive her 2022 annual performance bonus at the corporate achievement level.
Additional $100,000 cash payment in appreciation for her contributions as an early employee.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Giulia C. Kennedy

Global Chief Scientific Officer and Chief Medical Officer

VCYT · VERACYTE, INC.

Effective: 2022-12-31
Filed: December 14, 2022, 6:59 PM ET

On December 9, 2022, Giulia C. Kennedy, Ph.D, Global Chief Scientific Officer and Chief Medical Officer of Veractye, Inc. (the “Company”), and the Company agreed that she would depart from the Company, effective December 31, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Giulia C. Kennedy departed as Global Chief Scientific Officer and Chief Medical Officer at VERACYTE, INC..

Action: departed
Role: Global Chief Scientific Officer and Chief Medical Officer

Exact text from the filing

On December 9, 2022, Giulia C. Kennedy, Ph.D, Global Chief Scientific Officer and Chief Medical Officer of Veractye, Inc. (the “Company”), and the Company agreed that she would depart from the Company, effective December 31, 2022.

View on SEC.gov

VERACYTE, INC. filing history →

Source: SEC EDGAR

accession 0001384101-22-000162

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.